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older than those without (37.5 vs. 34.5, p = 0.0017). The prevalence rate among all 
patients were 7.6% for diabetes, 13.3% for hypertension, 23.4% for hyperlipidemia, 
as compared to 3.4%, 8.5% and 6.8% in patients without HAART. There were sta-
tistically significant differences for diabetes (p = 0.0294) and hyperlipidemia (p < 
0.0001). The difference for hypertension is boradline statistically significant (p = 
0.0601). The mean expenditure per patient per year of dyslipidemia drugs, hypo-
glycemic drug, antihypertensive drug, and sedative hypnotic drug were not statisti-
cally significant. CONCLUSIONS: Per previous literature reviews, the prevalence of 
diabetes, hypertension, hyperlipidemia for HIV-infected patients with HAART was 
confirmed and increasing year by year using the real world data in Taiwan. Good 
control of metabolic co-morbidities to reduce the risk of morbidity and mortality 
is highly recommended.
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OBJECTIVES: E. coli is the most frequently encountered pathogen in clinical set up 
causing devastating infections irrespective of age and gender resulting in signifi-
cant morbidity and mortality. E. coli isolates have been found resistant to variety 
of antibiotics commonly used in empirical therapy at hospitals and clinics. CTX-M, 
TEM and SHV type extended spectrum beta-lactamases are mainly responsible 
for this resistance. The aim of this study was to investigate the prevalence of CTX-
M, TEM and SHV beta-lactamases in clinical isolates of E. coli and to assess the 
resulted economic burden on the poor population. METHODS: E. coliisolates were 
collected from a tertiary care hospital between 2012 and 2013, and tested against 
several classes of antibiotics on Kirby- Bauer disk diffusion methods to check their 
multidrug resistance phenotype. Presence and identification of CTX-M, SHV and 
TEM beta-lactamases were confirmed on PCR. RESULTS: Overall resistance pat-
tern to the tested antibiotics was amoxicillin(80%), cefazolin(74%), cefotaxime(63%), 
ceftazidime(58%), gentamycin(58%), ciprofloxacin(89%), levofloxacin(51%), chloram-
phenicol(38%), erythromycin(83%), amoxicillin/clavulanic acid(82%) and trimetho-
prim/sulfamethoxazole(91%). The prevalence of different beta-lactamase types in E. 
coliisolates was CTX-M(72 %), TEM(67%) and SHV(53%). CONCLUSIONS: CTX-M, TEM 
and SHV beta-lactamases are responsible for such overwhelming resistance in these 
isolates. These enzymes are present on mobile genetic elements such as plasmids 
which are readily exchanged between diverse bacterial communities and leading 
this alarming resistance to epidemic level. More than 50% of population live below 
the poverty line in Pakistan and cannot afford or have excess to expensive treat-
ments, such resistance is challenging the very health care system of the country. 
Both rate of infections and resistance to antimicrobials is on the rise and is sped 
up by the unregulated sub-standard health practice in Pakistan. The current health 
and economic losses are incalculable but the more devastating consequences to the 
humanity and economy are not too far from reality.
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OBJECTIVES: H1N1 influenza infection associated with higher morbidity and mor-
tality because of associated severe complications like acute respiratory distress 
syndrome (ARDS) and multiple organs dysfunction syndrome. We conducted a ret-
rospective study to evaluate the clinical characteristics, different complication and 
management strategies adopted to treat H1N1 patients in a tertiary care centre. To 
study the clinical features, complication, different risk factors affecting the outcome 
along with different management strategies used in the patients with confirmed 
H1N1influenza infection. METHODS: The medical records of 141 patients were ana-
lyzed retrospectively who were admitted to KMC Hospital, Manipal, from June 2012 
through May 2014. RESULTS: Among the study population 51.1% were female with 
mean age of 32.54 years. Among 55.3% patients admitted without any significant 
medical history and 44.7% patients had major problems like diabetes mellitus, res-
piratory tract infections and bronchial asthma. Fever with headache was observed 
in 92.9% followed by cough (78.7%) and breathlessness (54.6%). According to severity 
of disease 53.2% patients were put on mechanical ventilation. All the patients were 
started with oseltemivir for influenza management. The co-infections were treated 
by beta-lactams (60.28%) and macrolides (41.11%). Diuretics were given in 32.46%, 
anti-anxiety in 31.90% patients and antipyretics, bronchodilators and corticoster-
oids as supportive care in all patients. Mean of hospitalization period was 8.5 days. 
During the hospitalization the patients developed different complications like res-
piratory tract infections (31.20%), ARDS (17.7%) and sepsis (14.4%). The mortality rate 
of the study population was found to be 29.1 %. CONCLUSIONS: We observed that 
outcome was associated with low oxygen saturation during admission, metabolic 
acidosis, abnormal chest x-rays, use of diuretics, corticosteroids and anti-anxiety 
drugs. We also found that the complications like ARDS, sepsis and respiratory tract 
infections also influence the mortality rate.
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OBJECTIVES: This study assessed length of stay (LOS), inpatient costs and mortal-
ity among hospitalized patients with cSSSI treated with ceftaroline compared with 
illness (RIH rate: 7.03%) of which 196 tested RSV-positive (RSVH rate: 1.76%). All RIHs 
were not or probably not related to palivizumab. 62 single or multiple SAEs were 
documented in 52 infants. Fourteen events in 6 patients out of 62 SAEs were hyper-
sensitivity reactions (moderate: 11; mild: 3). These were deemed possibly (n= 10) or 
probably (n= 4) related to palivizumab (rate: 0.00028 events per patient-month). The 
remaining 48 SAEs in 46 patients were categorized as not related (n= 39), probably 
not related (n= 5), and unclassifiable (n= 4). CONCLUSIONS: Using an active surveil-
lance system, a very small proportion of infants in the CARESS registry experienced 
SAEs that had a clear relationship with palivizumab and these events appear to 
be idiosyncratic. In routine practice, palivizumab appears to be a safe and well-
tolerated antibody for RSV infection prophylaxis in high-risk children.
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OBJECTIVES: While infectious disease societies recommend weight-based loading 
doses of 25-30 mg/kg in critically ill patients, published meta-analyses describe 
increased vancomycin related nephrotoxicity at these doses. Our objective was to 
assess incidence of nephrotoxicity with vancomycin in emergency department (ED) 
sepsis patients when compliant with these recommendations. METHODS: This was 
a retrospective cohort study performed in three EDs. An electronic health record 
(EHR)-based clinical decision support tool provided guidance at the point of order for 
IV vancomycin compliant with recommendations. Inclusion criteria: age ≥ 18 years, 
IV vancomycin order, and hospital admission. Exclusion criteria: no documented 
weight, hemodialysis-dependent, or < 2 creatinine (Cr) values. The primary outcome 
was incidence of nephrotoxicity within 5 days defined as at least 2 serial Cr higher 
than the initial measurement by at least 0.5 mg/dL or 50% increase. The secondary 
outcome was acute kidney injury (AKI) within 5 days, defined as any single increase 
in Cr by 0.5mg/dL or 50%. Analyses compared the incidence of nephrotoxicity and 
AKI between patients who received high dose (> 20 mg/kg) versus low dose (≤ 20 mg/
kg). Parametric data were compared using the t-test and categorical data with chi-
squared tests. RESULTS: An EHR-based query identified 2131 consecutive patients 
prescribed IV vancomycin over 6 months. Of these, 1330 patients met study criteria 
for the primary outcome and 1631 patients met criteria for the secondary outcome. 
Nephrotoxicity occurred in 8% of patients. High dose vancomcyin was associated 
with a lower rate of nephrotoxicity (6% vs 11%, p< 0.05) and a lower rate of AKI (8% 
vs 13%, p< 0.05). CONCLUSIONS: Initial dosing of vancomycin > 20 mg/kg according 
to guidelines was associated with a decreased rate of nephrotoxicity compared with 
low doses. Future analyses should distinguish between the occurrence of nephro-
toxicity due to disease progression in severe sepsis versus vancomycin exposure.
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OBJECTIVES: The aim of this study was to reassess the safety profile of fluoroqui-
nolones using the database of adverse drug reactions (ADR) Spontaneous report 
system and the purchases data of fluoroquinolones. METHODS: All ADRs reported 
related to fluoroquinolones were retrieved from Center for Drug Monitoring and 
Evaluation (CDME) of Hebei. Reports were classified by System Organ Classes with 
MedDRAÂ®. Consumption data (numbers of defined daily dose [DDDs]) were used 
as denominators.Reporting rate and types of ADRs between different drugs were 
checked with Pearson’s chi-squared test, and a p-value of < 0.05 was considered 
statistically significant. RESULTS: Fluoroquinolones common ADRs related to skin 
and subcutaneous tissue, gastrointestinal, general disorders and administration site 
conditions. No delayed ADR or death caused by ADR was reported. Ofloxacin, levo-
floxacin and ciprofloxacin showed the lowest reporting rate adjusted by consump-
tion data. CONCLUSIONS: These data suggest that different fluoroquinolones were 
characterized by different rates and types of ADRs. In current application of fluoro-
quinolones, clinicians did not pay sufficient attention to delayed-ADRs and ADRs 
resulting in glucose metabolism disorder, which might lead to more safety problems.
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OBJECTIVES: Highly active antiretroviral therapy (HAART) was available for HIV-
infected patients in Taiwan since 1997. HAART can effectively reduce mortality 
and morbidity, but it may also increase the risk and related drug costs of metabolic 
co-morbidities for HIV-infected patients. The aim of this research was to investi-
gate the prevalence and treatment costs of metabolic co-morbidities such as dia-
betes, hypertension, and hyperlipidemia between HAART treated and not treated 
patients. METHODS: We conducted a population-based study using 1M sampling 
version of the National Health Insurance Research Database (NHIRD) from Taiwan 
between 2010 and 2012. We extracted HIV-infected patients from both outpatient 
and inpatient with primary or secondary diagnosis of HIV (ICD codes 042-044). 
Treatments such as HAART and other related information were extracted. The 
prevalence and related drug costs of metabolic co-morbidities was estimated and 
comparison were made using SAS version 9.3. RESULTS: In the sampling database, 
there were 488 and 235 HIV-infected patients with and without HAART treatments. 
They were mainly male (94.6% vs. 90.2%, p = 0.0255), HAART treated patients were 
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OBJECTIVES: Hepatitis C (HCV) can lead to serious and costly liver complications 
including hepatocellular carcinoma and liver transplantation. Physicians have 
employed a “watch and wait” philosophy, placing their HCV patients in “ware-
houses” depending on disease genotype (GT), waiting for disease progression 
or the launch of new treatments. There has been a significant amount of press 
behind the high prices of new HCV products, but little has been discussed about 
the cumulative clinical and economic value they bring. One aspect of value is 
clinical benefit as measured by sustained viral response (SVR) rate. The objective 
was to determine how the average efficacy, measured by SVR, of HCV treatments 
changed from November 2013 to April 2014 and its potential impact on clinical 
and economic outcomes. METHODS: Using IMS Health National Prescription Audit 
Data, two time periods were defined: the past state of November 2013, when the 
fewest number of prescriptions for HCV treatments were written; the current 
state of April 2014, when the greatest number of prescriptions for HCV treatments 
were written. In order to compare the average SVR rate in these two time points, 
we calculated a weighted average SVR rate across GTs based on the proportion of 
patients in each GT and the market share of the following products: sofosbuvir, 
telaprevir, simeprevir, and boceprevir. RESULTS: Combining SVR rates with market 
share and the proportion of patients in each GT, the average SVR rate in November 
2013 and April 2014 was 74% and 86%respectively. This 12% increase across GTs 
was presumably driven by the launch of sofosbuvir. CONCLUSIONS: There are 
significant clinical and economic implications of overall improvement in SVR 
rate including impacts on liver transplant hospitalizations and end of life care. 
Additional HEOR considerations related to linking SVR rates to these outcomes 
will be considered further in the poster.
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OBJECTIVES: Assess the clinical effect of clostridial collagenase ointment (CCO) 
relative to undifferentiated wound dressings in the outpatient care setting for the 
treatment of venous leg ulcers (VLU). METHODS: Retrospective de-identified elec-
tronic medical records from 2007-2013 were extracted from the Intellicure Limited 
Data Set (I-LDS). The I-LDS extracts records from 96 hospital-based outpatient 
wound centers. A propensity score model using a 3 to 1 nearest neighbor match-
ing approach was performed to test for treatment effect and adjust for covariance 
between that received CCO and wounds treated with undifferentiated wound dress-
ings. RESULTS: A total of 9,314 patients, 22,312 wounds, and 186,023 visits for VLU 
were identified. The majority of patients was female (51.9%) with an average age of 
61.6 (SD= 17.7). Approximately 21.3% had a history of hypertension, 8.3% had a his-
tory of venous insufficiency with diabetes, and 2.5% received immunosuppressive 
agents. The mean wound surface area was 7.9cm2 (SD= 14.4). The average wound 
age was 8.5 months (SD= 27.8) and the average treatment duration was 2.9 months 
(SD= 4.9). Of the 22,312 wounds, approximately 13.2% received CCO (n= 2,954). The 
average number of CCO tubes used by patients was 2.6 (SD = 1.2). The average total 
visits where CCO was administered was 5.6 (SD = 16.2) and the average days of use 
with CCO was 12.3 (SD = 41.3). VLUs treated with CCO were significantly more likely 
(p< 0.005) to improve over the course of therapy relative to wounds treated with 
undifferentiated wound dressings alone. CONCLUSIONS: This analysis indicates 
that CCO provides a clinical benefit in the management of VLUs. Over the course 
of therapy VLUs treated with CCO demonstrate greater clinical improvement than 
VLUs treated with undifferentiated wound dressings.
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OBJECTIVES: To indirectly estimate the relative treatment effect of 12 weeks of 
treatment with SMV versus TPV in combination with response-guided background 
therapy of 24/48 weeks of Peginterferon/ribavirine (PR) in previously untreated 
patients with genotype 1 chronic hepatitis C virus infection, using patient-level 
data from the pivotal phase III-trials. METHODS: Patient-level data from three 
phase 3 trials in treatment-naive patients were pooled: ADVANCE (12 weeks 
of TPV-treatment (T12PR24/48)) and QUEST 1&2 (12 weeks of SMV-treatment 
(SMV12PR24/48) (with PR24/48 meaning response-guided duration of PR of 24 or 
48 weeks). To adjust for potential differences in patient characteristics across both 
trials, an adjusted odds ratio (OR) for reaching sustained viral response at week 
24 (SVR24) was estimated for a multivariate logistic regression model, includ-
ing genotype (G1a vs G1b), liver status (F0-2 vs F3-4), race (white, black, other), 
viral load (< 273K/273-< 800K/800-< 1200K/≥ 1200K IU/ml), age (≤ 45/45< -≤ 65/> 65), 
gender and BMI (< 25/25-< 30/30+) as baseline covariates. As a sensitivity analy-
sis, a similar analysis was generated excluding SMV-G1a patients with Q80K-
polymorphism. RESULTS: Patient numbers for T12PR24/48 and SMV12PR24/48 
were 363 and 521 respectively. 16.3% (n= 85) of SMV-patients were G1a with Q80K-
polymorphism. Overall, G1a (OR vs 1b = 0.75, p= 0.01), peg-interferon alpha-2b (OR 
vs peg-interferon alpha-2a = 0.60, p= 0.03), F3-4 liver status (OR vs F0-F2= 0.48, 
p< 0.0001), black race (OR vs white race = 0.56, p< 0.001) and viral load ≥ 1200K (OR vs 
< 273K = 0.28, p< 0.0001) were significantly associated with lower SVR24-rates. The 
observed SVR24-rates were 75% (TVR) versus 80% (SMV) (unadjusted OR= 0.75). The 
adjusted OR for T12PR24/48 to reach SVR24 compared to SMV12PR24/48 was 0.64 
[95% CI: 0.46;0.91] (p= 0.0113). When excluding Q80K-positive patients, the adjusted 
OR was 0.45 [0.31;0.67] (p< 0.0001). CONCLUSIONS: In absence of H2H-comparison 
of telaprevir versus simeprevir in treatment-naive patients, an adjusted indirect 
commonly used antibiotics to manage cSSSI (vancomycin, linezolid, daptomycin, 
tigecycline). METHODS: This retrospective study was conducted using the Premier’s 
Perspective Comparative Database (2010-2013), which includes over 170 million 
inpatient records from ~500 hospitals in the US. Hospitalization records for adults 
(≥ 18 years) with a diagnosis of cSSSI (identified using ICD-9-CM codes) were selected. 
cSSSI-related hospitalization records with evidence of intravenous ceftaroline, vanco-
mycin, daptomycin, linezolid or tigecycline were included. Using four separate logistic 
regression models propensity scores were estimated and patients in ceftaroline group 
were matched with patients in vancomycin, daptomycin, linezolid and tigecycline 
groups separately. Outcomes including LOS, inpatient costs and in-hospital mortality 
were compared among patients in ceftaroline group with the 4 other antibiotic groups 
using unadjusted (t-test and chi-square tests) tests. RESULTS: The sample sizes in the 
matched cohorts were as follows: a) ceftaroline/ vancomycin n= 2,834 (each group); 
b) ceftaroline/daptomycin n= 2,651; c) ceftaroline/tigecycline n= 2,606; d) ceftaroline/
linezolid n= 2,554. Mean duration for the study antibiotics ranged from 3.9 (vanco-
mycin) to 4.6 (tigecycline) days. Average LOS and inpatients costs were significantly 
(all P-values < 0.001) lower among patents in the ceftaroline group compared with 
patients in the vancomycin (mean LOS: 5.1 vs. 5.6;costs: $8,051 vs. $10,089), linezolid 
(LOS: 5.1 vs. 6.4;costs: $8,081 vs. $12,020), daptomycin (LOS: 5.0 vs. 6.3;costs: $7,824 vs. 
$10,227), tigecycline (LOS: 5.2 vs. 6.1;costs: $8,264 vs. $11,353) groups. In-hospital mor-
tality rate was ~1% for ceftaroline, vancomycin, tigecycline and daptomycin groups 
(except linezolid group 2%). CONCLUSIONS: Previously two-large global clinical trials 
(CANVAS 1 and 2) confirmed clinical efficacy of ceftaroline in-comparison with vanco-
mycin (standard-of-care) among patients with cSSSI. The current study serves as an 
initial-step towards confirming real-world effectiveness of ceftaroline in comparison 
with other commonly used antibiotics for cSSSI.
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OBJECTIVES: New influenza vaccines were developed to improve vaccine effec-
tiveness by expanding influenza B coverage and boosting hemagglutinin (HA) 
concentration. This research aims to assess the health impact of the new vac-
cines – high dose (HD) and quadrivalent influenza vaccines (IIV4), instead of IIV3, 
in adults aged 65 and older under Ontario’s Universal Influenza Immunization 
Program (UIIP). METHODS: An analytical model of one flu season was developed 
using Ontario’s physician visits and ED uses, and Canadian influenza hospitaliza-
tion and mortality rates with three age cohorts (age 65-74, 75-84, and 85 and above) 
at two levels of health risks (high and low). Ontario’s demographic data was from 
Statistics Canada. Vaccine efficacy and effectiveness against health outcomes were 
based on published studies. Sensitivity analyses with extreme values of all relevant 
parameters were conducted. RESULTS: Use of HD in place of IIV3 would avert 13,271 
influenza cases (range: 4,648-23,161) and 2,483 symptomatic non-consulting cases 
(range: 690-5,226) annually, and decrease health care utilization significantly – 3,818 
physician office visits (range: 1,530-5,520), 1,223 emergency department (ED) uses 
(range: 485-1,786), 772 hospitalizations (range: 442-1,223) and 341 deaths (range 
195-537). These reductions in health outcomes would avoid 857 outpatient antiviral 
treatments (range: 0-2,192) and eliminate 4,546 days of lost productivity (range: 
1,387-10,054) among Ontario’s elderly residents a year. IIV4 also showed a reduction 
in influenza-related health outcomes – 4,900 influenza cases (range: 3,364-11,817), 
1,178 symptomatic non-consulting cases (range: 499-2,665), with 102 hospitaliza-
tions (range: 51-175) and 33 deaths (range 17-57) avoided annually; as a result, 1,623 
(623-3,928) work days loss were prevented. CONCLUSIONS: Although potential net 
health impact would fluctuate annually depending on the variability of influenza 
viruses, both HD and IIV4 are expected to attain significant to modest reductions 
in influenza-associated morbidity and mortality in seniors. Those findings were 
proven to be robust in sensitivity analyses.
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OBJECTIVES: Analyze the relationship of clinical efficacy and trough concentration 
of Vancomycin treatment on Neonatal Bacterial Sepsis according to the high trough 
concentration standards. METHODS: Totally 73 neonates with bacterial sepsis were 
selected in our hospital. Their clinical information,labotatory results and patho-
gens were collected. Statistical analysis of the clinical efficacy, bacterial clearance 
rate and plasma concentration data after vancomycin treatment. RESULTS: The 
clinical total effective rate and bacterial clearance rate were 86.30% and 91.78%.
The average trough concentration of vancomycin was(12.57±6.83)mg·L-1 . The rate 
of reaching the high trough concentration standards was only 41.1%. Compared 
to < 10mg·L-1, the bacterial clearance rate and clinical efficacy of trough concen-
tration in 10-20mg·L-1 were much higher (P= 0.013, P= 0.001). 24 cases adjusted 
the dose according to the initial concentration data, but only 13 cases(54.17%)’s 
trough concentrations were in the standard range. CONCLUSIONS: Clinical efficacy 
of Vancomycin has a good correlation with trough concentration. But the rate of 
reaching the high trough concentration standard was low and TDM is needed for 
individualized therapy regimen.
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